Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Dec;19(6):1495-1496.
doi: 10.1007/s12072-025-10876-6. Epub 2025 Jul 24.

Systemic inflammation and prognosis in HCC: a closer look

Kaiyue Xu  1 , Xiaochen Chen  2
Affiliations
Comment

Systemic inflammation and prognosis in HCC: a closer look

Kaiyue Xu et al. Hepatol Int. 2025 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: This article has no conflicts of interest.

Comment on

  • Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma.
    Rocco A, Sgamato C, Pelizzaro F, Simeon V, Coccoli P, Compare D, Pinto E, Palano G, Foschi FG, Raimondo G, Missale G, Svegliati-Baroni G, Trevisani F, Caturelli E, Brunetto MR, Vidili G, Masotto A, Magalotti D, Campani C, Gasbarrini A, Azzaroli F, Rapaccini GL, Stefanini B, Sacco R, Mega A, Giannini EG, Cabibbo G, Di Marco M, Guarino M, Chiodini P, Farinati F, Nardone G. Rocco A, et al. Hepatol Int. 2025 Aug;19(4):915-928. doi: 10.1007/s12072-025-10806-6. Epub 2025 Mar 25. Hepatol Int. 2025. PMID: 40131621 Free PMC article.

References

    1. Rocco A, Sgamato C, Pelizzaro F, et al. Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma. Hepatol Int. 2025. https://doi.org/10.1007/s12072-025-10806-6 - DOI - PubMed
    1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604 - DOI - PubMed - PMC
    1. Birrer DL, Golcher H, Casadei R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. Pooled data from 3 randomized controlled trials. Ann Surg. 2021;274(5):713–720 - DOI - PubMed
    1. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905 - DOI - PubMed

LinkOut - more resources